New hope for tough CML: milder chemo before transplant shows promise

NCT ID NCT07259161

Not yet recruiting Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a reduced-toxicity chemotherapy regimen (thiotepa, melphalan, fludarabine) before a stem cell transplant in 40 people with blast-phase chronic myeloid leukemia (CML), an advanced and hard-to-treat stage. The goal is to see if this gentler approach can improve overall survival and reduce treatment-related deaths. Researchers will also track relapse rates and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: thiotepa, melphalan, and fludarabine (chemotherapy drugs)
What this could lead to: If successful, this could offer a safer way to prepare patients with advanced CML for a stem cell transplant, potentially improving survival and reducing severe side effects.
What could go wrong: This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. The treatment still carries risks like infection, organ damage, or graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CML,BLAST PHASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

blast phase chronic myelogenous leukemia, BCR-ABL1 positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CML,BLAST PHASE HSCT

More trials for these conditions

Other studies related to the condition(s) this trial covers.